sαKlotho protein is a useuful biomarker and a promising cardioprotective agent in acute heart failure

Abstract

Introduction

Acute heart failure (AHF) is a heterogeneous and etiologically complex syndrome with bad prognosis. sαKlotho (sαKL) is an antiaging protein with pleiotropic actions. The aim of the study was to assess the level and kinetics of sαKl during an episode of AHF and its long-term prognostic utility in population of AHF patients.

Material and methods

It was a prospective multicenter study, which enrolled 133 participants. 112 consecutive patients were admitted to the intensive cardiac care unit with diagnosis of AHF (age 68[IQR,60-75] years, ejection fraction 30%[IQR,20-38], new-onset AHF 46% of the population). 21 individuals consisted the control group. sαKl, N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined in serum at admission and at discharge. The main clinical outcomes assessed in the study were 3 year all-cause mortality or HF rehospitalization.

Results

sαKl concentration significantly increased during episode of AHF. A weak negative correlation was observed between sαKl and NT-proBNP at admission and discharge. Only patients with ischemic etiology of AHF did not have considerably elevated sαKl values at admission. Both, women and men had similar values of biomarker. Smoking did not affect sαKl in our study. Patients who developed the combined endpoint during 3 year follow-up presented poor increase in sαKl values on admission compared to control group (p=0.169) and weak biomarker kinetics during hospitalization as compared with group free of outcomes (p=0.01).

Conclusions

sαKl level is upregulated during an acute episode of HF and may acts as a useful biomarker. Weak reduction in sαKl levels during treatment indicate patients with poor long-term prognosis.

Introduction

Heart failure (HF) is a heterogeneous and etiologically complex syndrome [1]. Patients with HF often present with neuroendocrine and inflammatory activation, oxidative stress, ischemia, as well as congestion and hypoperfusion, which lead to multiorgan dysfunction [2,3]. Despite major advances in diagnosis and therapy, HF is still associated with an unacceptably high morbidity and mortality rates across the world, especially in the acute setting. While the gold standard biomarkers in management of HF are natriuretic peptides, several studies showed the pathophysiological significance of numerous molecules involved in myocardial dysfunction, such as cancer antigen – 125(Ca -125), adrenomedullin (ADM), fibroblast growth factor 23 (FGF-23)[4].

In 1997, Japanese scientists identified the Klotho gene associated with aging phenotypes [5]. Since then, there has been interest in the Klotho gene and its correlation with lifespan and also with neurodegenerative disorders, metabolic conditions, cardiovascular damage, and heart dysfunction. The Klotho gene is expressed at particularly high levels in the kidney and brain and encodes the Klotho protein. Interestingly, this molecule was reported to have antitumor activity [6]. The main isotype of the Klotho protein is called α-Klotho. There are 2 forms of α-Klotho: a single-pass transmembrane glycoprotein, which works as a coreceptor for (FGF-23), and secreted α-Klotho protein. The transmembrane type is cleaved by proteases and forms so called shed α-Klotho. Both secreted and shed forms belongs to soluble α-Klotho proteins (sαKl) and are released into the blood, urine, and cerebrospinal fluid [7-9].

sαKl are pleiotropic proteins with endocrine, autocrine and paracrine activation. In humans, the secreted form of sαKl predominates over the membrane form in serum [7]. However, in diseased heart cells, sαKl protein is upregulated and is derived from the cleavage of the membrane form [8]. Several studies documented that sαKl regulates mineral metabolism and inflammation and has antioxidative, antiapoptotic and antifibrotic activity [10-13]. An experimental study in a rat model revealed increased compensative sαKl production during ischemia/reperfusion injury in cardiac cells as well as the release of sαKl protein into the extracellular space. Thus, sαKl can probably serve as a useful marker of cell injury [14].

It is known that oxidative stress activates matrix metalloproteinases (MMPs) responsible for the degradation of contractile proteins in cardiomyocytes [15]. Additionally, the ARIC study indicated a link between increased plasma MMP levels and a higher risk of incident HF and arrhythmia [16]. By inhibiting MMPs, sα-Klotho can thus act as a cardioprotective agent [15]. It was also suggested that sαKl might be a novel predictor of response to treatment in the HF population [17]. Although a cross-sectional study showed that serum sαKl levels were negatively associated with chronic HF, little is known about the role of sαKl in patients with an acute episode of HF [18]. Considering its pleiotropic action, sαKl might prove to be a valuable biomarker in the setting of acute HF (AHF).

Thus, the aim of the current study was to assess the level and kinetics of serum sαKl during an episode of AHF and to establish the utility of sαKl in predicting long-term prognosis.

Material and methods

Study design

A total of 133 participants were enrolled in this study. The final sample included 112 consecutive patients admitted to the intensive cardiac care unit between June 2019 and January 2021. The follow-up lasted 3 years, Figure1. All patients received guideline-guided therapy of AHF at the discretion of the attending cardiologist [1]. The inclusion criteria were age over 18 years and hospitalization for an episode of AHF diagnosed within 24 hours of admission and requiring the use of at least one of the following: intravenous diuretics, catecholamines or mechanical circulatory support. Patients with active malignancy, autoimmune disease, and psychiatric disorders were excluded.

The control group was consistent with the study group in terms of age and gender. It included 21 individuals (mean [SD] age, 69 [17] years; 11 women and 10 men) without present or past acute coronary syndrome, myocardial infarction, percutanous coronary intervention, coronary artery bypass grafting, acute or chronic HF, acute kidney injury or chronic kidney disease. Median left ventricular ejection fraction 65% (IQR,60%-65%). The blood samples have been provided by the Biobank of Łukasiewicz Research Network – PORT Polish Centre for Technology Development.

The main clinical outcomes assessed in the study were 3-year all-cause mortality or rehospitalization due to HF.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Bioethics Committee at the Opole Medical Chamber (resolution no. 281 and 282/07 June 2019). All participants provided written informed consent prior to enrollment.

Biochemical analysis

Blood samples (EDTA and cloth samples) were collected during the first 24 hours from admission to the hospital and then at discharge. Each EDTA-sample was immediately centrifuged at 4000 RPM for 15 minutes to obtain plasma. The samples were then frozen at -80° until analysis. Plasma sαKl levels were measured in duplicate, using an enzyme-linked immunosorbent assay (Human soluble α-Klotho ELISA, Immuno-Biological Laboratories, Inc., Minneapolis, Minnesota, United States). The serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) were measured quantitatively using an automated sandwich electrochemiluminescence immunoassay (Roche Diagnostics GmbH, Mannheim, Germany). For NT-proBNP, levels above 300 pg/ml were considered significantly elevated and for hs-cTnT, the level of 0.014 ng/ml was established as the upper limit of normal. Other biochemical parameters were obtained from hospital laboratory and Biobank database.

Statistical analysis

Data were presented as either mean $\pm$ standard deviation (SD), median and interquartile range (IQR) or count and percentages. The type of distribution was verified using the Shapiro-Wilk test. Differences between groups were compared using the Student t-test for normally distributed variables and the Mann-Whitney U-test for non normally distributed variables. The pairwise test was used to compare 2 parameters within a single group. The results on graphs were expressed as box plots. A p-value of less than 0.05 was considered significant. All analyses were conducted using the R software v. 4.2.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Results

General characteristics

The demographic and clinical characteristics of patients with AHF are presented in Table I. The group included 112 patients admitted to the intensive cardiac care with AHF.

The mean (SD) age of patients was 65 (14.6) years, most patients were male. New-onset AHF was reported for 46% of the population. All patients suffered from multimorbidity and demonstrated significant HF with a median left ventricular ejection fraction of 30% (IQR, 20%-38%). Nearly half of the population had a history of coronary artery disease. Patients in critical condition were treated with catecholamines or using mechanical cardiac support.

Changes in biomarkers in the study group

In the whole study group, the median level of sαKl on admission was 670 pg/ml (IQR, 502-851 pg/ml). During hospitalization, sαKl levels decreased significantly to reach 542 pg/ml (IQR, 404-735 pg/ml) at discharge (p<0.001). On admission, patients presented also with increased levels of NT-proBNP, hs-cTnT, and high-sensitivity C-reactive protein (hs-CRP). Changes in the levels of these biomarkers are presented in Table I.

The levels of sαKl protein were similar between women and men on admission and at discharge (p=0,39 and p=0,89 respectively). In both genders, a significant reduction in sαKl levels was noted between admission and discharge: from 724 pg/ml (IQR, 535-892 pg/ml) to 519 pg/ml (IQR, 453-640 pg/ml) in women (p=0.002) and from 660 pg/ml (IQR, 501-836 pg/ml) to 550 pg/ml (IQR, 400-836 pg/ml) in men (p<0.001). On admission, serum sαKl levels in women and men were significantly higher in the study group vs the control group (p=0.049 and p=0.03 respectively), Figure 2.

In patients with the new-onset AHF, as well as with acute decompensated HF serum sαKl levels on admission were significantly higher than at discharge, 713 pg/ml (IQR, 525-886 pg/ml) vs 517 pg/ml (IQR, 403-667 pg/ml), p<0.001 and 634pg/ml (IQR, 502-836 pg/ml) vs 573pg/ml (IQR, 406-784 pg/ml), p=0.002. Of note, sαKl values on admission and discharge in both groups did not differ considerably (p=0.45 and p=0.31 respectively). There were significant differences between sαKl levels on admission in both groups vs the control group (p=0.006 and p=0.02 respectively), Figure 2.

4

In patients with AHF of ischemic etiology, sαKl levels decreased significantly between admission and discharge, 614 pg/ml (IQR, 461-810 pg/ml) vs 484 pg/ml (IQR, 391-725 pg/ml), p<0.001. Similarly in nonischemic subgroup, there was a significant reduction in sαKl levels between admission and discharge, 711 pg/ml (IQR, 556-895 pg/ml) vs 552 pg/ml (IQR, 437-736 pg/ml), p<0.001. A comparison of admission and discharge sαKl levels between ischemic and nonischemic etiology revealed that there were no differences (p=0.07 and p=0.26, respectively). Only in the nonischemic group, on admission, we observed significantly increased sαKl levels as compared with control (p=0.001), Figure 2.

In the presented study group, 39% were smokers. sαKlotho values in the group of smokers and non- smokers did not differ on admission and at discharge (p=0.64 and p=0.49, respectively). In both groups sαKlotho values dropped markedly between admission and hospital discharge. From 677 pg/ml (IQR,475-892 pg/ml) to 573 pg/ml(IQR, 402-831 pg/ml), p=0.007 in smokers group and from 664 pg/ml (IQR, 525-837 pg/ml) to 515 pg/ml (IQR,410-711pg/ml), p<0.001 in non-smokers. In both groups, a significant elevation in sαKlotho values was observed on admission compared to control group (p=0.049 and p=0.003, respectively), Figure 2.

Associations between sαKl levels and cardiovascular outcomes in patients with AHF

Nine patients (8%) died during hospitalization, and 103 patients (92%) were discharged from the hospital. During the 3-year follow-up, 27 of the 103 patients (26%) were hospitalized due to cardiovascular events, including 14 rehospitalizations (13.6%) due to HF. Death was reported for 38 patients (37%). Thus, the combined endpoint: all cause mortality or rehospitalizations due to HF was reached in 58 patients (52%). The flow of patients is presented in Figure 1.

Patients who developed the combined endpoint during follow-up were older, more often had acute decompensated HF phenotype, HF of ischemic etiology, chronic kidney disease and diabetes. They also had higher concentrations of hs-cTnT and NT-proBNP, Table II. In this subgroup, sαKl levels decreased significantly from admission to discharge, 614 pg/ml (IQR, 459-746 pg/ml) vs 490 pg/ml (IQR, 391-719 pg/ml), p=0.04, Figure 3A.

The subgroup that was free from cardiovascular events during follow-up showed significantly higher sαKl levels on admission as compared with group with outcomes (p=0.003), Table II, as well as with control group (p<0.001), Figure 2. Additionally, these patients showed a strong reduction in sαKl levels during hospitalization, 765 pg/ml (IQR, 594-880 pg/ml) vs 553 pg/ml (IQR, 453-784 pg/ml), p<0.001, Figure 3A. Both groups differed significantly in percentage sαKl reduction between admission and discharge (p=0.01), Figure 3B.

sαKl in the control group

In healthy individuals, serum sαKl levels are physiologically decreased because of the aging process [19]. The median level of sαKl protein in the control group was 522 pg/ml (IQR, 408-624 pg/ml).

Correlations between sαKl levels and other biomarkers

On admission, sα-Kl levels showed a weak negative correlation with the levels of NT-pro BNP (r = -0.21, p=0.03) and hs-CRP (r = -0.26, p=0.006). No significant correlation with hs-cTnT was shown (r = -0.14, p=0.13). At discharge, sαKl showed a weak negative correlation with NT-pro BNP and hs-CRP (r = -0.33, p=0.002 and r = -0.32, p=0.002, respectively).

Discussion

Our study showed that in critical conditions such as AHF, sαKl levels increase irrespective of sex, HF etiology or HF phenotype. Serum levels of sαKl protein are dynamic and show reduction during optimal treatment of AHF. Moreover, the study showed a negative association between sαKl levels and 3-year risk of all-cause mortality or HF rehospitalization.
sαKl is a protein with anti-inflammatory action, reduces oxidative stress and fibrosis caused by the activity of the renin-angiotensin-aldosterone system [7,9,19]. Experimental data on mouse model suggested cardioprotection with antyfibrotic and antyhypertrophic action [20]. It is known that sαKl levels decrease with age; therefore, serum concentration of biomarker may indicate the biological age. Various studies, however, reported different reference ranges for the sαKl protein [21,22]. Obesity,

6

chronic kidney disease and diabetes, which are potential risk factors for cardiovascular disease, are associated with low serum sαKl levels [23-24]. A meta-analysis of American populations suggested that low sαKl levels are associated with a higher risk of all-cause mortality [25].The above evidence indicates that sαKl plays a protective role in the body. Recent studies investigated changes in the levels of circulating sαKl, its reference ranges in acute cardiac conditions, and the use of sαKl as a biomarker of myocardial injury [15] and response to psychological stress [26]. Numerous data indicate that sαKl may improve the function of aging cells [27].

In our study, we assessed changes in sαKl in patients with AHF. In line with the study by Taneike et al [17], we noted significantly elevated sαKl levels compared with the control group. The levels of sαKl were assessed in subgroups according to sex as well as the phenotype, smoking habits and etiology of AHF. On admission, we noted considerably elevated sαKl levels in patients with new-onset HF and nonischemic etiology, as compared with the control group. In these patients, treatment resulted in a significant reduction in sαKl levels between admission and discharge. These findings are not surprising and confirm worse survival in patients with ischemic etiology of HF [28] and poor prognosis in those with acute decompensated HF linked to multiorgan damage [29-30].

Sex, non –modifiable risk factor, was also of our interest. Espuch-Oliver et al. investigated 345 healthy Andalusian volunteers and observed a negative association between sαKl levels and age, while there was no relationship with sex [21]. In an analysis of 19 patients (9 women) hospitalized for AHF, Taneike et al. revealed that sαKl levels were higher in men [17]. In our study, women constituted 25% of the whole population. Unlike Taneike et al, we did not observe significant differences in sαKl levels between women and men. On admission, both women and men with AHF had significantly higher sαKl levels than controls. This discrepancy might be due to different geographic region, living conditions, and race [31].

It is known, that smoking is related to premature aging, caused systemic inflammation and is leading to various disorders such as cardiovascular disease. It is not entirely clear what is the relationship between Klotho and smoking. Nakanishi et al. reported that smoking and psychological stress increases the level of sαKlotho in healthy individuals, suggesting compensation for harmful effects of smoking [32]. Onmaz et.al, found significantly decreased sαKlotho levels in smokers

compare to non-smokers [33]. In our study smokers and non-smokers, presented a significant elevation in sαKlotho values on admission compared to control group. Both groups did not differ on admission and at discharge (p=0.64 and p=0.49, respectively). This finding may mean that, smoking in our population of AHF patients was not important in sαKl dynamics.

Risk stratification in AHF is a main goal and necessary to better identification high-risk patients, who need close, much more intensive in-hospital treatment and monitoring after discharge. On the other hand low-risk patients may be discharged from hospital early and monitored in ambulatory care. It seems that, sαKl could be useful tool in risk assesment.

Our short, preliminary 12-month follow-up showed weak decrease in sαKlotho levels among patients with death or HF rehospitalization, Supplementary Figure S1.

Prolonged 3- year observation, revealed that patients free from cardiovascular events had significantly higher sαKl levels on admission than the control group. Moreover, we noted a major reduction in sαKl levels between admission and discharge in both groups, Figure 3A.

Patients who met the composite endpoint (death or HF rehospitalization) during the 3-year follow-up demonstrated significantly lower sαKl levels on admission compare to patients free from cardiovascular events. There were also significant changes in the levels of the biomarker during hospitalization, Figure 3A, however this group was characterized by a 2-fold lower reduction of sαKlotho values between admission and discharge compared to patients free from cardiovascular events, Figure 3B. Interestingly, at discharge, sαKl levels were lower than in the control group, Figure 2. Our findings suggest that sαKl probably has cardioprotective effects, and its production in AHF constitutes a compensatory reaction to oxidative stress and inflammatory response. Higher sαKl levels on admission were associated with a lower risk of death or rehospitalization due to HF during short 12- month and prolonged 3 –year follow up. Poor reduction in sαKl levels between admission and discharge indicates patients with bad prognosis. It seems that probably, supplementation with sαKl in these patients might improve their prognosis. Data from studies on animal model strongly suggest, that replenishment of sαKl protects against fibrosis in renal and cardiac diseases. sαKl was also found as a tumor growth inhibitor and potential therapeutic agent to promote the healing of aged injured skeletal muscles [6, 27]. Therapeutic potential of sαKlotho is a robust area of study for the development of

sαKL- based pharmaceuticals. Recent publications report, that small sαKl boosting molecules and gene therapy are intensively pursued by industry [6]. Findings from our study are in line with previous data [17] that confirmed the usefulness of sαKl in AHF, both as a biomarker and promising cardioprotective agent. Taking into account current knowledge [34], we see this new valuable molecule as commonly used, especially in screening health services and preventive medicine. The widespread use of sαKl, as a biomarker in the early diagnosis and management of age- related diseases, may help select high risk patient and facilitate therapeutic decision- making. Worthy to note, that early diagnosis might be cost-effective, for example in heart failure. Looking at the therapeutic potential of the molecule, it seems that sαKl might change management in many conditions and disorders. We believe, that all our activities are aimed at getting us closer to using this assay in common clinical practice.

Limitations of the study

First, this was a study with a limited number of enrolled patients. Thus, our findings should be confirmed in a survey with a larger sample size. Second, although we conducted therapy in accordance with the latest guidelines for HF our study did not include a specific therapy protocol. Many non-cardiovascular medication and nutraceuticals could affect the serum sαKl levels. It would be useful to perform an analysis of several medications affecting the sαKl level.

Conclusions

Our study showed that the sαKl level is upregulated during an acute episode of HF. Thus, it may be a useful biomarker for diagnosis and treatment. Poor kinetics in sαKl levels during treatment indicate patients with bad prognosis in the long term observation. Subjects with higher sαKl levels at admission tended to present better outcomes suggesting a promising cardioprotective role of this biomarker in AHF.

Acknowledgements

References

1. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021 Sep 21;42(36):3599-3726.

2. Harjola VP, Mullens W, Banaszewski M, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail*. 2017;19(7):821-836

3. Zymliński R, Sokolski M, Biegus J, et al. Multi-organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome. *Eur J Heart Fail*. 2019;21(6):744-750.

4. Zdanowicz A, Urban S, Ponikowska B, et al. Novel biomarkers of Renal Dysfunction and Congestion in Heart Failure. J. Pers. Med. 2022,12,898.

5. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature*. 1997;390(6655):45-51.

6. Abraham CR, Li A. Aging-suppressor Klotho: prospects in diagnostics and therapeutics.Ageing Res Rev.2022 Dec;82:101766

7. Matsumura Y, Aizawa H, Shiraki-Iida T, et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. *Biochem Biophys Res Commun*. 1998;242(3):626-30.

8. Poelzl G, Ghadge SK, Messner M, et al. Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels. *Sci Rep*. 2018;8(1):8429.

9. Bergmark BA, Udell JA, Morrow DA, et al. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. *Eur J Heart Fail*. 2019;21(4):462-470.

10. Wu SE, Chen WL. Soluble klotho as an effective biomarker to characterize inflammatory states. *Ann Med*. 2022;54(1):1520-1529.

11. Olejnik A, Franczak A, Krzywonos-Zawadzka A, Kałużna-Oleksy M, Bil-Lula I. The Biological Role of Klotho Protein in the Development of Cardiovascular Diseases. *Biomed Res Int*. 2018;2018:5171945.

12. Prud'homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. *Front Aging*. 2022;3:931331.

13. Lindner M, Mehel H, David A, et al. Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects. *Basic Res Cardiol*. 2020;115(5):51.

14. Olejnik A, Krzywonos-Zawadzka A, Banaszkiewicz M, Bil-Lula I. Klotho protein contributes to cardioprotection during ischaemia/reperfusion injury. *J Cell Mol Med*. 2020;24(11):6448-6458.

15. Olejnik A, Krzywonos-Zawadzka A, Banaszkiewicz M, Bil-Lula I. Klotho Protein Decreases MMP-Mediated Degradation of Contractile Proteins during Ischaemia/Reperfusion Injury to the Cardiomyocytes. *Int J Mol Sci*. 2022;23(24):15450.

16. Buckley LF, Agha AM, Dorbala P, et al. MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study. *Circ Heart Fail*. 2023;16(11):e010849.

17. Taneike M, Nishida M, Nakanishi K, et al. Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure. *Sci Rep*. 2021;11(1):2058.

18. Cai J, Zhang L, Chen C, Ge J, Li M, Zhang Y, et al. Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007-2016. Int J Cardiol. 2023;370:236-243.

19. Zhou L, Mo H, Miao J, et al. Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System. *Am J Pathol*. 2015;185(12):3211-23.

20. Hu MC, Shi M, Gillings N,et al. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int 91 (2017) 1104-1114.

21. Espuch-Oliver A, Vázquez-Lorente H, Jurado-Fasoli L, et al. References Values of Soluble α-Klotho Serum Levels Using an Enzyme-Linked Immunosorbent Assay in Healthy Adults Aged 18-85 Years. *J Clin Med*. 2022;11(9):2415.

22. Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM. Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. *Clin Biochem*. 2013;46(12):1079-1083.

23. Nie F, Wu D, Du H, et al. Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. *J Diabetes Complications*. 2017;31(3):594-598.

24. Shimamura Y, Hamada K, Inoue K, et al. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. *Clin Exp Nephrol*. 2012;16(5):722-9.

25. Kresovich JK, Bulka CM. Low Serum Klotho Associated With All-cause Mortality Among a Nationally Representative Sample of American Adults. *J Gerontol A Biol Sci Med Sci*. 2022;77(3):452-456.

26. Nakanishi K, Nishida M, Taneike M, et al. Implication of alpha-Klotho as the predictive factor of stress. J Investig Med. 2019;67(7):1082-1086.

27. Sahu A, Mamiya H, Shinde SN, et al. Age-related declines in α-Klotho drive progenitor cell mitochondrial dysfunction and impaired muscle regeneration. *Nat Commun*. 2018;9(1):4859.

28. Bollano E, Redfors B, Rawshani A, et al. Temporal trends in characteristics and outcome of heart failure patients with and without significant coronary artery disease. *ESC Heart Fail*. 2022;9(3):1812-1822.

29. Nawrocka-Millward S, Biegus J, Hurkacz M, et al. Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure. *Biomolecules*. 2021;11(11):1701.

30. Wójcicki K, Krysztofiak H, Dąbrowska K, et al. New-Onset Acute Heart Failure: Clinical Profile and one –year outcomes. Observations from the OP-AHF Registry. Kardiol Pol.2024;82(2):210-213.

31. Motiejūnaitė J, Akiyama E, Cohen-Solal A, et al. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. *Eur Heart J*. 2020;41(13):1357-1364.

32. Nakanishi K, Nishida M, Harada M, et al. Klotho – related molecules upregulated by smoking habit in apparently healthy men: A cross-sectional study. Sci Rep.5,14230 (2015).

33. Onmaz M, Demirbas N, Onmaz DE, et al. Effect of cigarette smoking on serum methylarginine and α-klotho levels. NMCD vol.33,3 (2023):602-609.

34. Nakanishi K, Nishida M, Taneike M, et al. Serum Klotho Levels Contribute to the Prevention of Disease Progression. Int. J. Gen. Med 2021 Jan 22:14:229-236.

Figure legends:

Figure 1.

Flowchart of 3-year follow-up in the study group.

Figure 2.

Comparison of sαKlotho concentration in serum by subgroups with control group at admission and

discharge.

Figure 3.

Changes of sαKlotho values during hospitalization in subgroups stratified by clinical course during 3-year

follow up. A- absolute values (median and interquartile range).B - ᴟ%.

Supplementary Figure S1.

Changes of sαKlotho values during hospitalization in subgroups stratified by clinical course during 1-year follow up. A- absolute values (median and interquartile range). B - ᴟ%.

.

Biomarker Study	Acute heart failure	Outcomes
N=133	Intravenous diuretics	3 year all -cause mortality
sαKlotho protein	Catecholamines	Heart failure hospitalization
	Mechanical cardiac support	

sαKlotho is upregulated in acute heart failure patient population regardless of etiology, phenotype and gender

Poor changes in sαKlotho values during hospitalization identifies patients with bad prognosis

Table I. Clinical characteristics of acute heart failure patient's group.

Variables	All patients (n=112)
Demographic data	
Age, years, mean (SD)	65(14.6)
Male gender, n (%)	77(74)
Total hospital stay, days, median (IQR)	15.5(10-25)
BMI kg/m^2, mean (SD)	29.8(6.7)
Smoking, n (%)	41(39)
„new onset" AHF, n (%)	52(46)
Ischemic etiology, n (%)	51(45)
Past medical history	
Hypertension, n (%)	72(69)
Myocardial infarction, n (%)	37(33)
Diabetes, n (%)	39(38)
Chronic kidney disease, n (%)	29(28)
Atrial fibrillation, n (%)	48(46)
Stroke, n (%)	8(7)
History of CABG, PCI n (%)	44(39)
Pacemaker, n (%)	16(14)
ICD, CRTD, n (%)	26(23)
Hospitalization data	
Cardiogenic shock, n (%)	8(7)
Cardiac arrest, n (%)	8(7)
Acute renal failure, n (%)	9(8)
Coronarography, n (%)	69(61.6)
Percutaneous coronary intervention, n (%)	23(26.7)
Coronary artery bypass graft, n (%)	6(5.4)
Mechanical cardiac support, n (%)	6(6)
Respiratorotherapy, n (%)	4(6.6)
Laboratory and echocardiographic parameters	
sαKlotho admission, pg/ml, median (IQR)	670(502-851)
sαKlotho discharge, pg/ml, median (IQR)	542(404-735)
hs-CRP admission, mg/l, median (IQR)	11(4-30)
hs-CRP last, mg/l, median (IQR)	8(3-26)
NT-proBNP admission, pg/ml, median (IQR)	5415(3257-13235)
NT-proBNP discharge, pg/ml, median (IQR)	1944(920-4960)
hs- cTNT admission, ng/l, median (IQR)	59(28-150)
hs- cTNT last, ng/l, median (IQR)	63(33-307)
LVEF on admission, %, median (IQR)	29.5(20-38)
LVEDd on admission, mm, median (IQR)	60(54-65)
LVEDs on admission, mm, median (IQR)	51(42-59)
TAPSE on admission, mm, median (IQR)	17(14-20)
IVC on admission, mm, median (IQR)	22(17-25)

Abbreviations: BMI, body mass index; hs-CRP, high-sensitivity
C-reactive protein; hs – cTNT, high-sensitive cardiac troponin T;
IVC- inferior vena cava; LVEDd, left ventricle end-diastolic dimension;
LVESd, left ventricle end-systolic dimension; LVEF, left ventricle
ejection fraction; NT-pro BNP, N-terminal prohormone of brain
natriuretic peptide; TAPSE, tricuspid annular plane systolic excursion.

Table. II Selected parameters of AHF patients, stratified according to 3-year all - cause mortality or heart failure rehospitalization

Variables	Event free N=54	Death or heart failure rehospitalization N=58	*P value*
Age, years, mean (SD)	61(18)	70(8.9)	0.016
Male gender, n (%)	36(67%)	48(83%)	0.049
BMI, mean (SD)	32(7)	28(5.3)	0.004
"new onset" AHF, n (%)	33(61%)	19(33%)	0.005
Ischemic etiology, n (%)	17(32%)	34(59%)	0.004
Diabetes, n (%)	17(32%)	25(43%)	0.283
CKD, n (%)	10(18.5%)	21(36%)	0.037
sα-Klotho admission, pg/ml, median (IQR)	765(594-880)	614(459-746)605,146	0.003
discharge, pg/ml, median (IQR)	553(453-784)	490(391-719)	0.162
NT-proBNP admission, ng/, median (IQR)	4318 (2836-8873)	7162 (3391-17108)	0.041
discharge, ng/l, median (IQR)	1451 (818-2963)	3222 (1220-8360)	0.011
hs-cTNT admission, ng/I, median (IQR)	37 (24-130)	68 (33-206)	0.042
last, ng/I, median (IQR)	43 (26-191)	95 (42-314)	0.063
hs-CRP admission, mg/l, median (IQR)	10(4-24)	11(4.5-33)	0.399
last, mg/l, median (IQR)	5.6(2.4-21)	10(4.4-30)	0.030
Hemoglobin admission, g/dl, median (IQR)	14(12-16)	12(11-14)	0.004
last, g/dl, median (IQR)	13.7(12-15.6)	12(10.5-14)	0.004
Urea admission, mg/dl, median (IQR)	38(31.4-51.5)	56(41.4-84)	<0.001
last, mg/dl, median (IQR)	45(34-53)	63(43-91)	<0.001
Creatinine admission, mg/dl, median (IQR)	1.1(0.97-1.26)	1.3(1.04-1.70)	0.021
last, mg/dl, median (IQR)	1.1(0.99-1.3)	1.2(0.93-1.69)	0.023
eGFR admission, mL/min/1.73m^2,median(IQR)	70(52.7-79.7)	54.9(37.8-75.5)	0.023
last, mL/min/1.73m^2,median (IQR)	63(52-83)	58(35-79)	0.027
Bilirubin admission, mg/dl, median (IQR)	0.66(0.41-0.95)	1.22(0.61-1.69)	0.037
last, mg/dl, median (IQR)	0.61(0.44-1.1)	0.85(0.60-1.52)	0.232
ASPAT admission, U/L, median (IQR)	37(25-59)	33.5(20.8-63.2)	0.482
last, U/L, median (IQR)	29(21.3-38.3)	31(22.5-41)	0.732
ALAT admission, U/L, median (IQR)	31(21-51.5)	22(13-54)	0.037
last, U/L, median (IQR)	33(15.5-43)	22.5(17-46.8)	0.623
Loop diuretics iv. ,n (%)	49(91)	55(95)	0.637
Nitrates iv., n (%)	15(28)	15(26)	0.988
Pressors iv., n (%)	7(13)	17(29)	0.262
Dobutamine iv., n (%)	2(4)	12(21)	0.015
Levosimendan iv., n (%)	7(13)	11(19)	0.544
ACEi ,n (%)	33(61)	22(38)	0.024
ARB, n (%)	6(11)	3(5)	0.419
Sacubitryl / Valsartan, n (%)	6(11)	7(12)	1.000
Beta- blocker, n (%)	46(85)	43(74)	0.225
SGLT2i, n (%)	3(6)	4(7)	1.000
MRA, n (%)	41(82)	27(68)	0.179
Oral diuretics, n (%)	45(90)	38(95)	0.628
Digoxin, n (%)	10(19)	12(21)	0.959

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ALAT, alanine transaminase; ASPAT, aspartate transaminase; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitive C-reactive protein; hs - cTNT,high-sensitive cardiac troponin T; MRA, mineralocorticoid receptor antagonist; NT-pro BNP, N-terminal prohormone of brain natriuretic peptide; SGLT2i, sodium glucose Co-transporter-2 inhibitor

Abbreviations: AHF, acute heart failure; HF, heart failure; CV, cardiovascular

Figure 1. Flowchart of 3-year follow-up in the study group

Abbreviations: ADHF, acute decompensated heart failure; AHF, acute heart failure; HF, heart failure; sαKlotho, soluble alfa Klotho; NS, not significant; * P < 0.05.
Control group (n=21), The median level of sαKl 522 pg/ml (IQR, 408-624 pg/ml). (1) Control group for women (n=11), The median level of sαKl 540 pg/ml (IQR, 428-636pg/ml). (2) Control group for men (n=10), The median level of sαKl 493 pg/ml (IQR,379-550pg/ml).

Figure 2. Comparison of sαKlotho concentration in serum by subgroups with control group at admission and discharge.

Figure 3. Changes of sαKlotho values during hospitalization in subgroups stratified by clinical course during 3-year follow up.
A- absolute values (median and interquartile range). B - ɤ%.